Nasal Decongestion and Obstructive Sleep Apnea

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Xylometazoline

Criteria

Inclusion Criteria:

• Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index >10/h)

• Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)

Exclusion Criteria:

• Nasal surgery within the last 6 months

• Current treatment with nasal decongestants or topical steroids

• Sleep disorders other than obstructive sleep apnea

• Internal medical or psychiatric disorders that interfered with sleep